Berlin, Germany, 12 November 2025 – ESMO – the European Society for Medical Oncology – is proud to launch the first edition of the ESMO Congress on Artificial Intelligence and Digital Oncology (AI&DO), taking place in Berlin from 12 to 14 November 2025. The event marks a pivotal moment in the Society’s commitment to advancing the responsible integration of digital innovations in oncology. More than 1,100 participants from across disciplines and sectors, representing Europe and other regions of the world are expected to attend.

The AI & Digital Oncology Congress represents a milestone in ESMO’s strategic efforts to foster a community of practice around the application of AI to clinical decision-making, while leading the way in setting standards and developing guidance for the safe use of AI in cancer care. This thought-leadership approach is reflected in the ESMO AI and Digital Oncology Hub – a platform designed to promote dialogue, share resources, and guide the oncology community through the opportunities and challenges posed by AI.

A Programme at the Intersection of Innovation and Clinical Relevance

The congress programme features a diverse array of presentations, scheduled to allow participants to follow all of them without competing parallel sessions:

• Multimodal AI for clinical decision support, showcasing applications in molecular tumour boards and real-world data integration.

• AI-based biomarkers for precision oncology, featuring discussions on validation frameworks and predictive modelling, including the announcement of the imminent publication of the ESMO Basic Requirements for AI-based Biomarkers in Oncology (EBAI) framework

• Generative AI and large language models, with keynote lectures featuring speakers from Google DeepMind and Harvard Medical School.

• Digital health in practice, exploring wearable technologies, remote monitoring, decentralised trials.

• Ethics, regulation, and patient perspectives, addressing trust, explainability and the societal implications of AI in oncology.

Industry leaders will showcase their latest developments in the area of AI and digital oncology, while academic experts will share insights into the evolving landscape of AI-driven research and its clinical implementation.

A Framework for Safe and Effective AI Integration

The congress anticipates the publication of the ESMO Basic Requirements for AI-Based Biomarkers in Oncology (EBAI) – the first comprehensive guidance for the validation and clinical use of AI-based biomarkers, which will appear soon in Annals of Oncology, ESMO’s flagship peer-reviewed journal.

This new framework builds on the Society’s earlier release of the ELCAP guidance on the safe use of large language models in oncology, further demonstrating ESMO’s proactive stance in navigating the digital transformation of cancer care.

Opportunities for interviews with leading speakers and contributors are available upon request.